NCT04883957View on ClinicalTrials.gov

Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 5, 2021

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Mature B-cell Malignancies
Interventions
DRUG

BGB-11417

Film-coated tablets administered orally as specified in the treatment arm.

Trial Locations (11)

100034

Peking University First Hospital, Beijing

100044

Peking University Peoples Hospital, Beijing

200032

Affiliated Zhongshan Hospital of Fudan University, Shanghai

215006

The First Affiliated Hospital of Soochow University, Suzhou

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

330006

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang

410013

Hunan Cancer Hospital, Changsha

430030

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan

450000

Henan Cancer Hospital, Zhengzhou

510060

Sun Yat Sen University Cancer Center, Guangzhou

518020

Shenzhen Peoples Hospital, Shenzhen

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT04883957 - Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies | Biotech Hunter | Biotech Hunter